← Back to headlines
Gilead to Acquire Cancer Drug Developer Arcellx for Up to $7.8 Billion
Gilead Sciences announced its plan to acquire cancer drug developer Arcellx in a deal valued at up to $7.8 billion, as pharmaceutical groups continue to acquire smaller biotech firms.
23 Feb, 11:02 — 23 Feb, 12:13
The Story
Analyzing sources…
Source Diversity
Source Diversity
Low (24/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 1/5 buckets covered0/33
Far L
Left
Center2
Center (2)
marketwatchFT
Right
Far R
Geographic diversity— 2 regions9/34
US1UK1
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
FTVery High57d ago
Gilead to buy cancer drug developer Arcellx for up to $7.8bn
Deal comes as pharmaceutical groups rush to acquire smaller biotech firms with proven drug pipelines
Read full article →marketwatchMostly Factual57d ago
Gilead shows its belief in its partner’s cancer treatment with a $7.8 billion buyout
Arcellx’s stock is heading toward a record after the $7.8 billion deal to be acquired by Gilead.
By Tomi Kilgore
Read full article →Coverage Timeline
First report: FT · 23 Feb, 11:02|Full coverage: 2 · 1h|Window: 1h
Left-leaningCenterRight-leaning
